Glaukos Co. (NYSE:GKOS) Receives $99.80 Average PT from Brokerages

Shares of Glaukos Co. (NYSE:GKOS) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $99.80.

GKOS has been the topic of a number of recent research reports. Needham & Company LLC upped their target price on shares of Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, February 27th. Mizuho increased their price objective on shares of Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Truist Financial reissued a “buy” rating and set a $110.00 price objective on shares of Glaukos in a research report on Monday, April 8th. Finally, Wells Fargo & Company increased their price objective on shares of Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, February 22nd.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 474 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $90.37, for a total value of $42,835.38. Following the transaction, the chief financial officer now owns 54,916 shares in the company, valued at approximately $4,962,758.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Alex R. Thurman sold 434 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $95.33, for a total value of $41,373.22. Following the transaction, the chief financial officer now owns 54,166 shares in the company, valued at approximately $5,163,644.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Alex R. Thurman sold 474 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total transaction of $42,835.38. Following the completion of the sale, the chief financial officer now directly owns 54,916 shares of the company’s stock, valued at $4,962,758.92. The disclosure for this sale can be found here. Insiders have sold 242,357 shares of company stock worth $22,857,372 in the last quarter. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Glaukos

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GKOS. National Bank of Canada FI purchased a new stake in Glaukos during the 4th quarter valued at approximately $46,000. GAMMA Investing LLC purchased a new stake in Glaukos during the 4th quarter valued at approximately $55,000. Quadrant Capital Group LLC grew its holdings in Glaukos by 54.8% during the 4th quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier’s stock valued at $74,000 after buying an additional 329 shares in the last quarter. CWM LLC grew its holdings in Glaukos by 309.5% during the 3rd quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,046 shares in the last quarter. Finally, Caldwell Sutter Capital Inc. grew its holdings in Glaukos by 5,860.0% during the 1st quarter. Caldwell Sutter Capital Inc. now owns 1,490 shares of the medical instruments supplier’s stock valued at $140,000 after buying an additional 1,465 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Down 0.8 %

NYSE:GKOS opened at $100.11 on Friday. The firm’s 50-day moving average price is $92.21 and its 200-day moving average price is $81.42. The company has a market capitalization of $5.02 billion, a PE ratio of -36.01 and a beta of 1.08. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78. Glaukos has a 1-year low of $45.38 and a 1-year high of $103.66.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). The business had revenue of $82.40 million during the quarter, compared to analysts’ expectations of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.53) earnings per share. On average, equities analysts predict that Glaukos will post -2.18 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.